LabCorpLaboratory Corporation of America® Holdings (LabCorp), Burlington, NC, introduces of an expanded testing menu to help clinicians diagnose, treat, and monitor the course of Inflammatory Bowel Disease (IBD).

The company offers an expanded IBD testing profile that helps to identify IBD patients and differentiate between ulcerative colitis and Crohn’s disease.

The IBD Expanded Profile includes ulcerative colitis and Crohn’s disease-specific antibody markers that improve diagnostic sensitivity and provide valuable prognostic information regarding the severity of disease.

For patients diagnosed with IBD, LabCorp’s TPMT Enzyme Activity assay can be used prior to thiopurine

Gastrointestinal tract disorders are often presented with nonspecific symptoms and are difficult to diagnose, especially in primary care settings.

IBD is one of the most common and serious gastrointestinal disorders. The two clinically distinctive forms of IBD are ulcerative colitis and Crohn’s disease. Treatments can also be complicated, involving immunosuppressant therapies, biological drugs, and/or surgery.

drug treatment to assess dosing levels and potential adverse drug reaction. Once a patient has started thiopurine treatment, physicians can use the thiopurine metabolites test to help optimize ongoing dosing to reach and maintain therapeutic goals and avoid possible drug toxicity. The company also offers testing for patients treated with new biological drugs such as infliximab that allow physicians to monitor drug concentration levels and assess the impact of anti-infliximab antibody levels on drug efficacy.

These enhancements to the company’s IBD test menu are adjuncts to its broader offering of digestive disease testing that includes cost-efficient cascade testing to help physicians diagnose Irritable Bowel Syndrome and non-Celiac Gluten Sensitivity.

On another front, LabCorp Clinical Trials has been selected as a preferred provider for full-service global central lab services and biomarker testing by Bristol-Myers Squibb Company.

The 5-year agreement builds on a longstanding partnership between the two companies during which LabCorp’s global central lab, biomarker, and specialty testing capabilities have supported various Bristol-Myers Squibb early and late-stage clinical development programs.

[Source: LabCorp]